<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377919</url>
  </required_header>
  <id_info>
    <org_study_id>DeniseMafra6</org_study_id>
    <nct_id>NCT04377919</nct_id>
  </id_info>
  <brief_title>Effects of Cranberry Supplementation on Chronic Kidney Disease Patients.</brief_title>
  <official_title>Effects of Cranberry Supplementation on Chronic Kidney Disease Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal Fluminense</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal Fluminense</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic kidney disease (CKD) have several complications that are linked to&#xD;
      oxidative stress and inflammation, and among the most recently studied is the alteration of&#xD;
      the intestinal microbiota. Considering this scenario, bioactive compounds have been&#xD;
      considered as a therapeutic alternative in the modulation of intestinal microbiota as well as&#xD;
      transcription factors such as nuclear-kappa factor B (NF-κB) and factor 2 nuclear&#xD;
      factor-related erythroid 2 Nrf2), involved with oxidative stress and inflammation. Among&#xD;
      several foods, cranberry is a fruit rich in flavonoids and other polyphenols, which has&#xD;
      antioxidant, anti-inflammatory and immunoregulatory actions and may be an adjuvant treatment&#xD;
      for CKD complications. However, clinical evidence evaluating the effects of cranberry is&#xD;
      limited and there are no studies specifically involving patients with CKD. Thus, the present&#xD;
      randomized crossover double-blind crossover with placebo-controlled washout period will aim&#xD;
      to evaluate the effects of cranberry supplementation on the modulation of the intestinal&#xD;
      microbiota and expression of transcription factors as well as cytokine levels inflammatory&#xD;
      effects of CKD patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a longitudinal study with a randomized crossover design, double-blind,&#xD;
      placebo-controlled, and with washout period. Thirty non-dialysis patients of both genders,&#xD;
      aged between 18 and 60 years and with CKD stage3-4 (glomerular filtration rate &lt; 59&#xD;
      mL/min/1.73 m2) will be included in the study. Pregnant patients, smokers and those under use&#xD;
      of antibiotics in the last 3 months, or in use antithrombotic, pre-, pro- or synbiotic&#xD;
      supplements, antioxidant supplements or habitual cranberry intake will be excluded. In&#xD;
      addition, those with autoimmune and infectious diseases, cancer, liver diseases and HIV will&#xD;
      also not be included in the study. The patients that fulfill the eligible criteria and sign&#xD;
      the ethical informed consent will be randomized to either Group A (Cranberry) or Group B&#xD;
      (Placebo). During 12 weeks, patients allocated in group A will receive capsules containing&#xD;
      cranberry extract (Vaccinium macrocarpon to 25% anthocyanosides 160mg, equivalent to 40mg&#xD;
      anthocyanosides), once daily (lunch), totaling 500mg / day and those allocated in the group B&#xD;
      will receive a placebo (500mg of corn starch). After the supplementation period, a 12-week&#xD;
      washout will be performed for subsequent crossover of the supplement. The randomization will&#xD;
      be computed in the ratio of 1: 1, with block size of 15 (Cranberry group and Control), to&#xD;
      receive cranberry or placebo. This project was approved by the Ethics Committee of the&#xD;
      Faculty of Medicine-UFF, n. 2.653.752.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antioxidants and anti-inflammatory biomarkers</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate the supplementation effects in anti-inflammatory biomarkers- Nrf2 and antioxidants enzymes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory biomarkers</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate the supplementation effects in inflammatory biomarkers- factor nuclear kappa B (NFkB), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemical Routine</measure>
    <time_frame>12 weeks</time_frame>
    <description>Urea, creatinine, albumin, lipid profile plasma levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Uremic toxins</measure>
    <time_frame>6 months</time_frame>
    <description>P-cresol, indoxyl sulfate plasma levels</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <condition>Inflammation</condition>
  <condition>Oxidative Stress</condition>
  <condition>Gastrointestinal Microbiome</condition>
  <arm_group>
    <arm_group_label>Cranberry</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of 2 capsules with 500mg (Miralys Ltda) of cranberry extract per day, for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of 2 capsules with 500mg of maize starch per day, for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cranberry</intervention_name>
    <description>The patients will receive 2 capsules per day containing 500mg of cranberry extract for 8 weeks</description>
    <arm_group_label>Cranberry</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The patients will receive 2 capsules per day containing 500mg of maize starch for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Chronic Kidney Disease in conservative treatment&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
          -  Must be able to swallow tablets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients pregnant&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Using antibiotics in the last 3 months&#xD;
&#xD;
          -  Using antioxidant supplements in the last 3 months&#xD;
&#xD;
          -  Usual intake of cranberry fruit or extract&#xD;
&#xD;
          -  Clinical diagnosis of infectious diseases&#xD;
&#xD;
          -  Clinical diagnosis of Cancer&#xD;
&#xD;
          -  Clinical diagnosis of AIDS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise Mafra, phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal Fluminense</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Denise Mafra</name>
      <address>
        <city>Niterói</city>
        <state>Rio De Janeiro</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>May 3, 2020</last_update_submitted>
  <last_update_submitted_qc>May 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

